Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Central Nervous System

Categories

[Search within category]

Inhibition Of Lipofuscin Aggregation By Molecular Tweezers

UCLA researchers in the Departments of Neurology and Molecular Therapy & Medical Genetics have developed a novel approach toward broad inhibition of lipofuscin aggregation.

Inhibition Of Stress Granule Formation Through Manipulation Of UBAP2L

Stress granule (SG) formation has been suggested as a two-step process, with initial formation of a dense stable SG ‘‘core’’ followed by accumulation of proteins containing intrinsically disordered regions (IDRs) and low-complexity domains (LCDs) into a peripheral ‘‘shell’’ through a process involving liquid-liquid phase separation (LLPS). Recently, SGs have been associated with human neurodegenerative disorders characterized by the presence of toxic insoluble protein aggregates. This link is most compelling in the case of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), where numerous disease-causing mutations are purported to interfere with LLPS-dependent growth and dynamics of SGs.

Integrative Leakage Correction For Contrast Agent Extravasation In Dynamic Susceptibility Contrast (DSC) - MRI

UCLA researchers in the Department of Radiological Sciences have developed a new technique for more accurately estimating relative cerebral blood volume (rCBV) from dynamic susceptibility contrast (DSC) perfusion MRI by improved modeling and correction of contrast agent leakage.

Intelligent Flexible Spinal Cord Stimulators For Pain And Trauma Management Through Neuromodulation

UCLA researchers in the Department of Neurosurgery and Electrical Engineering have developed a novel closed-loop spinal cord stimulator device that is small and flexible.

Innovation of the Non-Obstructive Cerebral Shunt System

Dr. Subramaniam from the UCLA Department of Neurosurgery has developed a novel cerebral shunt design that allows self-clearing of shunt obstruction. This innovation reduces complications caused by cerebral shunt blockage and prolongs the lifetime of shunt implants.

Antibody Selection to Prevent or Treat Alzheimer’s Disease

Therapeutic antibodies have been developed to prevent or slow the cognitive decline in Alzheimer’s disease (AD) but with limited clinical success to date. These treatment failures suggest that antibodies vary in their therapeutic efficacy and that more effective antibodies or combinations of antibodies need to be identified. To address this issue, researchers at UCI have developed a novel screening platform that can identify antibodies that may prevent or treat AD or other neurodegenerative disorders with high efficacy from human blood.

A Novel Method and Protocol to Induce Pluripotent Stem Cells Toward Astrocyte Differentiation

Rett syndrome (RTT) is a devastating disease that affects 1 in every 10,000 children born in the United States, primarily females. RTT patients undergo apparently normal development until 6-18 months of age, followed by impaired motor function, stagnation and then regression of developmental skills, hypotonia, seizures and a spectrum of autistic behaviors. Rett syndrome is a rare disease that shares certain pathways with major developmental disorders such as autism and schizophrenia, increasing the potential impact. There is no cure for Rett syndrome and the animal model does not entirely recapitulate the human disease. Thus, having the possibility to screen drugs directly in human neurons is a major milestone.

Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders

Researchers at the University of California, Davis have developed small molecule inhibitors to prevent or reverse the progression of neurodegenerative diseases or symptoms.

Trainable Filter Emulator For Real-Time Control Systems

Researchers led by Dr. Cong from the Department of Computer Science at UCLA have developed an algorithm that enables real-time control in brain-machine interface applications.

Ultra-Dense Electrode-Based Brain Imaging System With High Spatial And Temporal Resolution

UCLA researchers in the Department of Bioengineering have developed a novel integrated brain imaging system that utilizes an ultra-dense electrode-based device. This system provides high resolution of functional brain images spatially and temporally.

Fabrication Of An Array For Transcutaneous Spinal Cord Stimulation

UCLA researchers in the Department of Bioengineering developed a novel transcutaneous spinal cord stimulation device that employs microneedles to continuously deliver effective and uniform electrical current to spinal cords. The device does not irritate tissues and uses much lower electrical power than conventional devices.

Combination Hormone Therapy for Multiple Sclerosis

This invention identifies FDA-approved selective estrogen receptor modulators (SERMs), that when used alone or in combination with estrogen promote remyelination and thus can potentially be used as therapeutics for multiple sclerosis (MS).

A Cell-Based Seeding Assay for Huntingtin Aggregation

UCLA researchers from the Department of Psychiatry has created a novel cell-based seeding assay for sensitive, specific and high throughput detection of mutant Huntingtin proteins in biological samples.

Genes, Proteins and Small Molecule Networks Responsible for Neuronal Regeneration

Through integrative analyses of the regeneration-associated gene expression profiling after peripheral nervous system (PNS) injury, combined with multi-level bioinformatics and experimental validation of network predictions, UCLA researchers in the Department of Neurology have identified a small molecule drug that significantly accelerates and improves dorsal root ganglia (DRG) neurite outgrowth in vitro and optic nerve outgrowth in vivo.

NOVEL BRAIN TECHNOLOGY FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS USING ELECTRICAL STIMULATIONS

This invention is a novel technology developed to treat a patient’s neurological and/or psychiatric conditions. It consists of a system of implantable devices and computational algorithms that not only has autonomous control in sensing and stimulation of electrical signals in the patient’s brain, but also enables interactions with the external environment, thereby enhancing training and learning.

Biomarker of Dyskinesia to Customize Medication or Deep Brain Stimulation for Parkinson's Disease Patients

This invention has provided methods for detecting dyskinesia in Parkinson’s disease patients and provided a way to titrate current treatment to maximize benefits while minimizing side effects.

Mobile Phone Based Fluorescence Multi-Well Plate Reader

UCLA researchers have developed a novel mobile phone-based fluorescence multi-well plate reader.

Pathway-Dependent Inhibition Of Proteopathic Seed Transmission

UCLA researchers in the Department of Neurology have developed a novel approach to stop the propagation of proteopathic diseases, which could be applied to wide range of neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease.

Immunotherapy Against Aß-Mediated Inhibition of ADAM10 Activity

UCLA researchers in the Department of Neurology have developed a novel immunotherapy targeting a previously unexplored pathway of Aβ toxicity in Alzheimer’s disease.

Immunotherapy for Treatment of Neuromyelitis Optica (NMO)

This invention comprises compositions and methods for treatment of neuromyelitis optica (NMO) spectrum disorders using anti-aquaporin-4 (AQP4) antibody lacking effector function.

Nell-1 Regulates Neurogenesis And Nervous System Function

UCLA researchers in the Division of Plastic and Reconstructive Surgery at the Geffen School of Medicine and researchers at the School of Dentistry have identified neural EGFL Like 1 (Nell-1) protein as an essential molecule involved in neurogenic development and nervous system functional regulation.

Generation of a New Animal Model for Studying Multiple Sclerosis

Human multiple sclerosis affects millions of people and is predominately a chronic immune-mediated disease of the central nervous system (CNS). The disease is estimated to affect 2-3 million in 2013 on a global basis. The value of the multiple sclerosis therapeutics market will rise from $17.2 billion in 2014 to approximately $20 billion by 2024. However, the pathogenic mechanisms underlying disease progression are not understood and currently there is no cure for the disease. Therapeutic drugs are developed using two classical experimental autoimmune/allergic encephalomyelitis (EAE) models. Experimental autoimmune/allergic encephalomyelitis (EAE) is the most extensively studied animal model for human MS. However, EAE mainly affects spinal cord white matter, whereas human MS displays demyelination and axonal injuries in the cerebral and cerebellar cortex. In addition, human MS progression cannot be studied in EAE.The second major animal model is RNA virus (TMEV, Theiler’s murine encephalomyelitis virus) induced demyelination, which is considered as a more relevant model to human MS. However, demyelination is caused by persistent TMEV virus infection that is not observed in human MS. Additionally, the TMEV virus can only infect mouse, but not other rodents or primates, limiting its utilization in establishing MS models in other species. Because the TMEV virus is a mouse pathogen, animal facilities often refuse such studies. A new animal model that more closely resembles the pathology of human multiple sclerosis is urgently needed.

Anti-Oxidant Response Modifiers as Treatment for HIV-Associated Neurocognitive Disorder

UCLA researchers have identified anti-oxidative response modulators as a potential treatment for HIV-associated neurocognitive disorders (HAND).

Novel Anti-Bacterial, Anti-Fungal Nanopillared Surface

Medical devices are susceptible to contamination by harmful microbes, such as bacteria and fungi, which form biofilms on device surfaces. These biofilms are often resistant to antibiotics and other current treatments, resulting in over 2 million people per year suffering from diseases related to these contaminating microbes. Death rates for many of these diseases are high, often exceeding 50%. Researchers at UCI have developed a novel anti-bacterial and anti-fungal biocomposite that incorporates a nanopillared surface structure that can be applied as a coating to medical devices.

  • Go to Page: